Tenaya Therapeutics Inc TNYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNYA is a good fit for your portfolio.
News
-
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
-
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
-
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
-
Tenaya Therapeutics Announces Pricing of Underwritten Offering
-
Tenaya Therapeutics Gets FDA Fast-Track Designation for TN-201
Trading Information
- Previous Close Price
- $4.22
- Day Range
- $4.22–4.36
- 52-Week Range
- $1.66–8.09
- Bid/Ask
- $4.30 / $4.32
- Market Cap
- $338.41 Mil
- Volume/Avg
- 100,974 / 538,627
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 140
Comparables
Valuation
|
Metric
|
TNYA
|
RCKT
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.15 | 4.03 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
TNYA
RCKT
CBAY
Financial Strength
|
Metric
|
TNYA
|
RCKT
|
CBAY
|
|---|---|---|---|
Quick Ratio | 4.60 | 7.69 | 10.70 |
Current Ratio | 4.91 | 7.80 | 10.96 |
Interest Coverage | — | −138.48 | −5.27 |
Quick Ratio
TNYA
RCKT
CBAY
Profitability
|
Metric
|
TNYA
|
RCKT
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −49.04% | −38.11% | −30.06% |
Return on Equity (Normalized) | −57.07% | −43.04% | −51.97% |
Return on Invested Capital (Normalized) | −56.79% | −43.72% | −30.87% |
Return on Assets
TNYA
RCKT
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cyrqlpxsk | Yft | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mxbtpvrll | Vctmmz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tzxysssd | Hjzrc | $97.8 Bil | |
MRNA
| Moderna Inc | Xdnqtswp | Ntxy | $41.3 Bil | |
ARGX
| argenx SE ADR | Pzqlsyzmc | Bhpr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xzddtcjxr | Txdfl | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vwzyjwq | Nynmbp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zhdnrbh | Kjppxp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lsmfbtblmq | Cjdbl | $12.5 Bil | |
INCY
| Incyte Corp | Jcsfzdls | Nbdzmty | $11.6 Bil |